Article
Mechanistic characterization of GS-9190 (Tegobuvir), a novel nonnucleoside inhibitor of hepatitis C virus NS5B polymerase.
Antimicrobial agents and chemotherapy - 1 Sept 2011
Shih I-Hung, Vliegen Inge, Peng Betty, Yang Huiling, Hebner Christy, Paeshuyse Jan, Pürstinger Gerhard, Fenaux Martijn, Tian Yang, Mabery Eric, Qi Xiaoping, Bahador Gina, Paulson Matthew, Lehman Laura S, Bondy Steven, Tse Winston, Reiser Hans, Lee William A, Schmitz Uli, Neyts Johan, Zhong Weidong
Abstract excerpt
GS-9190 (Tegobuvir) is a novel imidazopyridine inhibitor of hepatitis C virus (HCV) RNA replication in vitro and has demonstrated potent antiviral activity in patients chronically infected with genotype 1 (GT1) HCV. GS-9190 exhibits reduced activity against GT2a (JFH1) subgenomic replicons and GT2a (J6/JFH1) infectious virus, suggesting that the compound's mechanism of action involves a genotype-specific viral...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.